Skip to main content

AlphaLISA Human CTLA4-CD86 Binding Kit, 500 Assay Points

The AlphaLISA® CTLA-4/CD86 binding kit is designed for the detection of binding activity between human CTLA-4 and CD86, using a fast and simple homogeneous AlphaLISA assay (no wash steps). This assay can be used to screen for small molecules that inhibit binding, as a competitive ligand binding (CLB) assay to screen therapeutic blocking antibodies, and for potency assays.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Part number: AL3047C
Unit Size: 500 Assay Points
List price: USD 2,833.00
Your price:
USD 2,833.00
USD 2,833.00 /each
Part number: AL3047F
Unit Size: 5,000 Assay Points
List price: USD 17,310.00
Your price:
USD 0.00
USD 17,310.00 /each



  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad range of affinities
  • High avidity
  • Results in less than 3 hours
  • Half the time of an ELISA assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a biotinylated CD86 binds to the Streptavidin-coated Alpha Donor beads, while His tagged CTLA-4 is captured by Anti-His AlphaLISA Acceptor beads. When CD86 binding to CTLA-4 happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Human Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152 (cluster of differentiation 152), is a cell membrane receptor and a member of immunoglobulin superfamily. CTLA-4 is expressed once a T cell becomes active and modulates T cell signals by blocking the CD80 (B7.1) and CD86 (B7.2) ligands from binding to CD28. CTLA-4, functioning as an immune checkpoint, downregulates T cell immune responses. Because of its profound inhibitory role blocking CTLA-4 and CD80 or CD86 binding has been considered as promising therapeutic target for human autoimmune disease and cancers.


Protein-protein interactions
Assay Points
Assay Target Class
Automation Compatible
Detection Method
Shipping Conditions
Shipped in Blue Ice
Therapeutic Area
Unit Size
500 Assay Points

Video gallery


1-1 of 1 Resources
Flyer Icon
Reagent solutions for autoimmunity research.

Advance your autoimmune disease research and benefit from Revvity broad offering of reagent technologies

SDS, COAs, Manuals and more Illuminator

SDS, COAs, Manuals and more

Are you looking for technical documents for this product. We have housed them in a dedicated section., click on the links below to explore.

Scroll Icon